|Bid||0.0050 x N/A|
|Ask||0.0030 x N/A|
|Day's range||0.0050 - 0.0060|
|52-week range||0.0040 - 0.0260|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sholom Feldman has been the CEO of Cann Global Limited (ASX:CGB) since 2007, and this article will examine the...
Sydney, Australia, July 10, 2020 - (ABN Newswire) - Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020. The announcement included a 1 for 4 pro-rata non-renounceable Entitlement Offer for eligible shareholders of fully paid ordinary shares (New Shares) on the basis of 1 New Share for every 4 existing shares held at the record date of 9 July 2020 (Record Date), together with 1 for 2 free attaching options (New Options). Eligible shareholders may apply for Additional New Shares and Additional New Options in addition to their entitlement.
Sydney, Australia, June 15, 2020 - (ABN Newswire) - On the 26th of February 2018, Cann Global Limited's (ASX:CGB.AX - News) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement with Professor David (Dedi) Meiri and his team at the Technion, Israel's renowned university, to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS). The Technion's lab is widely considered to be the leading cannabis research lab globally and has the unique ability to comprehensively profile cannabinoid composition for a variety of cannabis strains and to purify single Phytocannabinoids (molecules synthesised by the cannabis plant) and create suspect profiles for examination in different studies.